2 Reasons Gilead Sciences' NASH Program Could Bounce Back

Gilead Sciences (NASDAQ: GILD) pours more resources into developing an effective NASH treatment than any of its peers. Unfortunately, the candidate from Gilead's NASH program that was closest to the finish line recently failed. Here's what you need to know about what happened and how Gilead's NASH program can bounce back.